News Image

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Provided By PR Newswire

Last update: Jan 13, 2025

– Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 – 

Read more at prnewswire.com

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (7/25/2025, 8:01:00 PM)

4.35

-0.08 (-1.81%)



Find more stocks in the Stock Screener

Follow ChartMill for more